Literature DB >> 19895731

[Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma].

Zhan Yu1, Wei Luo, Qi-Chao Zhou, Qin-Hua Zhang, De-Hua Kang, Meng-Zhong Liu.   

Abstract

BACKGROUND AND
OBJECTIVE: The gross tumor volume (GTV) obviously reduces after induction chemotherapy (IC) for primary locoregionally advanced nasopharyngeal carcinoma (NPC). This study was to investigate the impact of changing gross tumor volume delineation on the dose distribution and clinical treatment outcome after IC.
METHODS: From January 2008 to April 2009, 24 patients with Stage III-IVb primary locoregionally advanced NPC were treated with TPF regimen IC followed by intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy . The primary GTVs were delineated into two parts: the post-IC primary GTV (GTVpost-IC-NP), and the region of pre-IC primary GTV minus GTVpost-IC-NP (GTVpre-post-IC-NP). The dose distributions of two plans with GTVpost-IC-NP or pre-IC primary GTV were assessed by analyzing ten cases. The clinical treatment outcome and toxicity of all patients were observed.
RESULTS: The post-IC GTV was significantly smaller than the pre-IC GTV (primary GTV 25.5 cm3 vs. 51.1 cm(3),P=0.001; lymph nodes GTV 9.1 cm(3) vs. 31.4 cm(3), P=0.035; primary + lymph nodes GTV 33.2 cm(3) vs. 82.6 cm(3),P=0.004), the overall GTV with an average shrinkage of 61%. The high dose region was also smaller after IC (volumes covered by 64.4 Gy were 422.9 cm3 vs. 457.9 cm3, P=0.003; 274.2 cm(3) vs.334.5 cm(3) by 68 Gy, P=0.041). The complete response rate was 38% after IC, and 100% three month after radiotherapy. The toxicity of following IMRT with concurrent chemotherapy was similar to that of IMRT with concurrent chemotherapy alone. With median follow-up of 9 months, the locoregionally control rate was 100% and only one patient presented metastasis 15 months after treatment.
CONCLUSIONS: TPF regimen IC could significantly reduce tumor volume. The following IMRT with GTVpost-IC-NP plan reduced the high dose region, which didn't add toxicity while had excellent short-term treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895731     DOI: 10.5732/cjc.009.10435

Source DB:  PubMed          Journal:  Ai Zheng


  11 in total

1.  Future of Radiotherapy in Nasopharyngeal Carcinoma.

Authors:  Xue-Song Sun; Xiao-Yun Li; Qiu-Yan Chen; Lin-Quan Tang; Hai-Qiang Mai
Journal:  Br J Radiol       Date:  2019-07-09       Impact factor: 3.039

2.  Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases.

Authors:  Chao Lin; Xue-Song Sun; Sai-Lan Liu; Xiao-Yun Li; Nian Lu; Xin-Ling Li; Lin-Quan Tang; Ling Guo
Journal:  Cancer Res Treat       Date:  2020-03-10       Impact factor: 4.679

3.  Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.

Authors:  Jun-Fang Liao; Qun Zhang; Xiao-Jing Du; Mei Lan; Shan Liu; Yun-Fei Xia; Xiu-Yu Cai; Wei Luo
Journal:  Cancer Commun (Lond)       Date:  2019-06-27

4.  Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Lei Wang; Zheng Wu; Dehuan Xie; Ruifang Zeng; Wanqin Cheng; Jiang Hu; Shaomin Huang; Shu Zhou; Rui Zhong; Yong Su
Journal:  Cancer Res Treat       Date:  2018-08-13       Impact factor: 4.679

5.  Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.

Authors:  Di-Han Liu; Xiao-Yu Zhou; You-Guang Pan; Si Chen; Zheng-Hao Ye; Gang-Dong Chen
Journal:  Cancer Med       Date:  2019-12-20       Impact factor: 4.452

6.  Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update.

Authors:  Ting Jin; Qun Zhang; Dong-Hua Luo; Feng Jiang; Qi-Feng Jin; Yuan-Yuan Chen; Xiao-Zhong Chen; Wei-Min Mao
Journal:  Transl Oncol       Date:  2019-11-16       Impact factor: 4.243

7.  Radiation-induced gray matter atrophy in patients with nasopharyngeal carcinoma after intensity modulated radiotherapy: a MRI magnetic resonance imaging voxel-based morphometry study.

Authors:  Lei Shi; Feng-Lei Du; Zong-Wen Sun; Lan Zhang; Yuan-Yuan Chen; Tie-Ming Xie; Pei-Jing Li; Shuang Huang; Bai-Qiang Dong; Min-Ming Zhang
Journal:  Quant Imaging Med Surg       Date:  2018-10

8.  Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study.

Authors:  Wang-Zhong Li; Shu-Hui Lv; Guo-Ying Liu; Hu Liang; Xiang Guo; Xing Lv; Kui-Yuan Liu; Meng-Yun Qiang; Xi Chen; Sophie Z Gu; Chang-Qing Xie; Wei-Xiong Xia; Yan-Qun Xiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-08-24       Impact factor: 8.013

9.  Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy.

Authors:  Sai-Lan Liu; Xue-Song Sun; Li-Ting Liu; Rui Sun; Dong-Hua Luo; Qiu-Yan Chen; Huan-Xin Lin; Li Yuan; Lin-Quan Tang; Ling Guo; Hai-Qiang Mai
Journal:  Aging (Albany NY)       Date:  2020-03-27       Impact factor: 5.682

10.  Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.

Authors:  Sai-Lan Liu; Xue-Song Sun; Hao-Jun Xie; Qiu-Yan Chen; Huan-Xin Lin; Hu Liang; Yu-Jing Liang; Xiao-Yun Li; Jin-Jie Yan; Chao Lin; Zhen-Chong Yang; Shan-Shan Guo; Li-Ting Liu; Qing-Nan Tang; Yu-Yun Du; Lin-Quan Tang; Ling Guo; Hai-Qiang Mai
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.